Copyright
©The Author(s) 2020.
World J Hepatol. Aug 27, 2020; 12(8): 436-450
Published online Aug 27, 2020. doi: 10.4254/wjh.v12.i8.436
Published online Aug 27, 2020. doi: 10.4254/wjh.v12.i8.436
Ref. | Tissue | Main findings in NAFLD patients compared to healthy control | Main findings in NASH patients compared to NAFL patients |
Puri et al[26], 2009 | Plasma | Increased: DAG, TAG, MUFA, dihomo-gamma-linolenic acid, palmitoleic acid, oleic acid, palmitoleic acid to palmitic acid ratio in NAFLD; stepwise increase in lipoxygenase (LOX) metabolites 5-HETE, 8-HETE, and 15-HETE from healthy controls to NAFL to NASH; 11-HETE in NASH compared with controls. | |
Zheng et al[81], 2012 | Plasma phospholipids fatty acid composition | Increased: Dihomo-gamma-linolenic acid (C20: 3n-6), total SFA in phospholipids. | |
Loomba et al[89], 2015 | plasma eicosanoid lipidomic profile | Increased: 15-HETE, 5,6-diHETrE. | Increased: 11,12-diHETrE, dhk PGD2, and 20-COOH AA. |
Walle et al[80], 2016 | Serum (fatty acid composition) | Increased: Palmitoleic acid in CE in individuals with NAFLD. | Increased: SFA in TAG were higher in subjects with NASH, myristic acid in CE and TAG, Stearic acid in TAG. |
Tiwari-Heckler et al[27], 2018 | Serum | Increased: PC and SM in NAFL and NASH. | Increased: PE in patients with NASH. |
Ma et al[27], 2016 | Plasma | Increased: PS and PI in NAFL and NASH, DHA and AA in PS in NAFL and NASH. |
- Citation: Kartsoli S, Kostara CE, Tsimihodimos V, Bairaktari ET, Christodoulou DK. Lipidomics in non-alcoholic fatty liver disease. World J Hepatol 2020; 12(8): 436-450
- URL: https://www.wjgnet.com/1948-5182/full/v12/i8/436.htm
- DOI: https://dx.doi.org/10.4254/wjh.v12.i8.436